On April 13, 2021 BridgeBio Pharma, Inc. (NASDAQ: BBIO) reported a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers (Press release, BridgeBio, APR 13, 2021, View Source [SID1234577969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"UC Davis is a top-tier research university and we feel honored to get the chance to collaborate closely with the talented team there as we work to discover, create, test and deliver breakthrough medicines for people who are suffering from genetic diseases," said BridgeBio founder and CEO Neil Kumar, Ph.D.

Under the agreement, the BridgeBio team will work closely with investigators at UC Davis to seek and evaluate potential research projects in genetic disease and precision oncology.

"We have a great appreciation for BridgeBio’s vision to create new pathways that connect innovative research to potential treatments for diseases that may not otherwise be pursued in the marketplace," said Bill Tucker, interim associate vice chancellor for Innovation and Technology Commercialization at UC Davis. "We are thrilled to combine our expertise in the hope of expanding the impact of our research to help those in need."

BridgeBio collaborates with stand-out academic institutions, including UC Davis, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page.

With a diverse pipeline encompassing investigational therapies for rare diseases and genetically validated cancers, BridgeBio provides the insights and support needed to rapidly progress therapeutic research from labs to clinical development. BridgeBio intends to develop similar long-term partnerships based on trust, engagement, science and respect to support its mission of developing life-changing medicines for patients with genetically driven conditions as quickly and safely as possible.

On April 13, 2021 BridgeBio Pharma, Inc. (NASDAQ: BBIO) reported a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers (Press release, BridgeBio, APR 13, 2021, View Source [SID1234577968]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to begin collaborating with Roswell Park, which is renowned for its excellence in cancer research and its mission to set the gold standard for treating patients with genetically driven cancers," said BridgeBio CEO and founder Neil Kumar, Ph.D.

Under the partnership, BridgeBio will work with scientists at Roswell Park Comprehensive Cancer Center to evaluate new research and development opportunities in oncology that have promise to advance and potentially provide clinical benefit for patients. Select therapeutic programs may be pursued by BridgeBio, in close collaboration with Roswell Park Comprehensive Cancer Center scientists, who would remain deeply involved in the ongoing development of these investigational therapies.

"Collaborating with BridgeBio opens up a platform of new resources to support the incredible Roswell Park innovators working on new ways to care for cancer patients with dire unmet need," said Roswell Park Comprehensive Cancer Center President and CEO Candace S. Johnson, Ph.D. "The ability to tap into this network of expertise means greater visibility for our teams and enables a quicker path to the clinic for our most promising ideas and inventions in areas like genetics, bioinformatics and molecular biology."

BridgeBio partners with stand-out academic institutions, including Roswell Park Comprehensive Cancer Center, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Oregon Health & Science University, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page.

With a diverse pipeline encompassing investigational therapies for both rare diseases and genetically validated cancers, BridgeBio provides the insights and support needed to rapidly progress therapeutic research from labs to clinical development. BridgeBio intends to develop similar long-term partnerships based on trust, engagement, science and respect to support its mission of developing life-changing medicines for patients with genetically driven conditions as quickly and safely as possible.

On April 13, 2021 BridgeBio Pharma, Inc. (NASDAQ: BBIO) reported a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with genetically driven conditions (Press release, BridgeBio, APR 13, 2021, View Source [SID1234577967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We feel privileged to have the opportunity to work with OHSU to focus on developing potential therapies for diseases with clear genetic drivers and severe unmet need," said BridgeBio founder and CEO Neil Kumar, Ph.D. "OHSU was one of the first research institutions we connected with in the early days of BridgeBio, and we look forward to deepening our relationship through close collaboration with their scientists as we strive to help patients together."

This arrangement builds on five years of informal collaborations between the two organizations. Under the agreement, the BridgeBio team will work closely with OHSU scientists and investigators to advance potential medicines for patients with genetically driven conditions, including cancers.

"BridgeBio’s approach to identifying and developing novel therapies allows them to interact with multiple investigators at OHSU who are studying a wide variety of diseases," said OHSU Chief Research Officer and Executive Vice President Peter Barr-Gillespie, Ph.D. "We believe their expertise and infrastructure will help lead to the rapid development of new drugs. We see this collaboration as an important part of our efforts to bring OHSU innovations to clinical significance."

BridgeBio collaborates with stand-out academic institutions, including OHSU, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with Brown University, GlycoNet, The Lundquist Institute, Roswell Park Comprehensive Cancer Center, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio partners with, please visit Our Partners page.

With a diverse pipeline encompassing investigational therapies for rare diseases and genetically validated cancers, BridgeBio provides the insights and support needed to rapidly progress therapeutic research from labs to clinical development. BridgeBio intends to develop similar long-term partnerships based on trust, engagement, science and respect to support its mission of developing life-changing medicines for patients with genetically driven conditions as quickly and safely as possible.

On April 13, 2021 BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University reported a formal collaboration to advance research in genetically driven neurological disorders into potential life-changing medicines for patients (Press release, BridgeBio, APR 13, 2021, View Source [SID1234577966]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Brown University is a leader in critical neurology research, and we look forward to partnering with their scientists to focus on discovering and advancing new targeted treatment approaches to potentially address challenging and complex diseases of the brain," said BridgeBio founder and CEO Neil Kumar, Ph.D.

Under the partnership, BridgeBio will work with scientists at Brown to evaluate new discoveries in neurology research that have promise to advance toward clinical investigation. Select therapeutic programs may be spun out and advanced in BridgeBio affiliate companies, with an opportunity for Brown University scientists to support as company leaders and guide ongoing development.

"BridgeBio’s unique approach and support for having researchers stay involved in development made it an easy decision to partner with them in translating our discoveries into potential medicines for patients in need," said Neil Veloso, Executive Director of Brown Technology Innovations at Brown University. "We look forward to the collaboration and empowering Brown faculty to progress their research."

BridgeBio partners with stand-out academic institutions, including Brown University, to support research around genetically driven conditions and is focused on rapidly translating findings into meaningful treatments for patients. Today BridgeBio also announced formal partnerships with GlycoNet, The Lundquist Institute, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center, University of California, Davis and University of California, San Diego – for a total of 20 partnerships between BridgeBio and leading academic and research institutions to date. For a list of some of the institutions BridgeBio is partnered with, please visit Our Partners page.

As part of an ongoing effort to translate research in genetically driven conditions toward therapeutic development, BridgeBio will continue to seek long-term partnerships with similar institutions that are rooted in trust, engagement, science and respect in order to drive forward its mission of developing transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers as quickly and safely as possible.

On April 13, 2021 Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, reported the completion of a $189 million Series B financing (Press release, Repertoire, APR 13, 2021, View Source [SID1234577963]). Joining Flagship Pioneering, Repertoire’s institutional founder and principal backer, are new and existing investors including Softbank Vision Fund 2i, the Public Sector Pension Investment Board (PSP Investments), the Alaska Permanent Fund, Invus, and others. Proceeds from this financing will support further expansion of the company’s proprietary DECODE discovery platform, accelerate its clinical and preclinical pipeline, expand Repertoire’s team, and enhance its manufacturing capabilities. Founded by Flagship Pioneering, Repertoire has raised more than $350 million in the aggregate to date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are making tremendous progress toward unlocking the full potential of therapeutically modulating the immune system by decoding the interactions between T cells and antigens to create new classes of immune medicines for cancer, immune disorders, infectious diseases, and other serious diseases," said John Cox, CEO of Repertoire. "This financing round will support the broad application of our DECODE platform to define and understand the complete repertoire of T cell receptor-antigen pairs that drive cellular immunity. The insights we glean from this information will enable a new era of novel immune medicines designed to exploit these critical interactions."

This financing also supports the advancement of multiple clinical programs in immuno-oncology using Repertoire’s proprietary antigen-primed multi-clonal cytokine enhanced T cell products in solid tumors. The PRIME IL-15 program in advanced metastatic solid tumors is underway, with a data readout anticipated later this year. The PRIME IL-12 program in HPV-16+ solid tumors will be initiated by mid-year. Both clinical programs represent novel first of their kind immune medicines in oncology.

"All roads to cellular immunity pass through the immune synapse," said Douglas Cole, M.D., co-founder, and Chairman of the Board of Repertoire Immune Medicines and Managing Partner of Flagship Pioneering. "Repertoire’s innovative platform makes it possible to elucidate the features of the immune synapse that drive clonal behavior. Applying this knowledge will revolutionize the discovery and development of immune medicines."